The lower rating came from HSBC, which cited too much optimism around its new weight-loss pill, and the strength of Novo ...

Which stock rocked the table with a double downgrade? The Investment Committee reveals today's Calls of the Day!

Eli Lilly And Co (NYSE:LLY) stock is 1.6% lower to trade at $870.31 at last check, after a rare double downgrade from HSBC to "reduce" from "buy," and a price-target cut to $700 from $1,150. The ...

Rather counterintuitively, following some promising news about a pipeline drug, one analyst tracking Eli Lilly (NYSE: LLY) ...

The trial met its primary objectives, showing the pill’s effectiveness in helping patients with Type 2 diabetes achieve ...

The mid-stage trial results announced by the pharmaceutical giant showed that patients taking orforglipron lost an average of ...

Shares in pharmaceuticals giant Eli Lilly (LLY) were looking perkier today after it ramped up its battle to get a key ...

Shares in pharmaceuticals firm Eli Lilly (LLY) rose today after it said it was suing companies ripping off its weight-loss ...

If approved, the pill is expected to be far easier to administer than current injectables — and far easier to manufacture.

Over the last couple of years, one of the best pharma stocks to own has been Eli Lilly ( LLY 14.56%). But now, an investment ...

Shares of Eli Lilly jumped 16% Thursday morning after the pharmaceutical company released clinical trial results for its oral ...

Lilly shares are up 14.2% in response to the news, while shares of its rivals in the GLP-1 weight loss market, Novo Nordisk ( ...